370 related articles for article (PubMed ID: 30448957)
21. Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting
Yoon J; Ballas L; Desai B; Jadvar H
World J Nucl Med; 2017; 16(3):229-236. PubMed ID: 28670183
[TBL] [Abstract][Full Text] [Related]
22. Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.
Achard V; Lamanna G; Denis A; De Perrot T; Mainta IC; Ratib O; Iselin C; Miralbell R; Garibotto V; Zilli T
Med Oncol; 2019 Jun; 36(8):67. PubMed ID: 31190232
[TBL] [Abstract][Full Text] [Related]
23. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
Ceci F; Castellucci P; Mamede M; Schiavina R; Rubello D; Fuccio C; Ambrosini V; Boschi S; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
[TBL] [Abstract][Full Text] [Related]
24. Role of PET-CT with
Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.
Gacci M; Cai T; Siena G; Minervini A; Torshizi MF; Bartolini M; Giannì G; Saieva C; Ceroti M; Detti B; Livi L; Pupi A; Carini M
Scand J Urol; 2014 Jun; 48(3):259-67. PubMed ID: 24255954
[TBL] [Abstract][Full Text] [Related]
26. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
[TBL] [Abstract][Full Text] [Related]
27. Value of
García JR; Compte A; Buxeda M; Mourelo S; Soler M; Blanch A; Valls E; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):197-203. PubMed ID: 32165153
[TBL] [Abstract][Full Text] [Related]
28. Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer.
Pizzuto DA; Annunziata S; Ieria FP; Caldarella C; Isgrò MA; Lanni V; Bencivenga G; Rufini V; Giordano A
Q J Nucl Med Mol Imaging; 2019 Dec; 63(4):387-393. PubMed ID: 29345442
[TBL] [Abstract][Full Text] [Related]
29. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
[TBL] [Abstract][Full Text] [Related]
30. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
Mamede M; Ceci F; Castellucci P; Schiavina R; Fuccio C; Nanni C; Brunocilla E; Fantini L; Costa S; Ferretti A; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
[TBL] [Abstract][Full Text] [Related]
31. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
[TBL] [Abstract][Full Text] [Related]
32.
Michaud L; Touijer KA; Mauguen A; Zelefsky MJ; Morris MJ; Lyashschenko SK; Durack JC; Humm JL; Weber WA; Schöder H
J Nucl Med; 2020 Jun; 61(6):827-833. PubMed ID: 31862801
[TBL] [Abstract][Full Text] [Related]
33. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.
Schillaci O; Calabria F; Tavolozza M; Caracciolo CR; Finazzi Agrò E; Miano R; Orlacchio A; Danieli R; Simonetti G
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):589-96. PubMed ID: 22231016
[TBL] [Abstract][Full Text] [Related]
34. Role of
Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM
Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596
[TBL] [Abstract][Full Text] [Related]
35. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml.
Witkowska-Patena E; Giżewska A; Dziuk M; Miśko J; Budzyńska A; Walęcka-Mazur A
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):343-348. PubMed ID: 31780781
[TBL] [Abstract][Full Text] [Related]
37. Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes.
Linxweiler J; Saar M; Al-Kailani Z; Janssen M; Ezziddin S; Stöckle M; Siemer S; Ohlmann CH
Surg Oncol; 2018 Jun; 27(2):138-145. PubMed ID: 29937163
[TBL] [Abstract][Full Text] [Related]
38. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
39. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
40. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
